News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Breaking Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
Arvinas' VEPPANU becomes the first FDA-approved PROTAC drug for ESR1-mutated, ER+/HER2- advanced breast cancer, marking a breakthrough in protein degradation therapy.
Latest News
Aptar Pharma Advances FDA-Funded Research Contract for Drug Approvals
Aptar Pharma has made notable advancements on its multi-year FDA-funded research contract, which could influence drug approval processes. This development holds significant implications for investors and pharmaceutical teams.
FDA's Guidance on Animal Testing Alternatives: Industry Concerns
The pharmaceutical industry is raising concerns about the FDA's recent guidance on animal testing alternatives, calling for significant improvements. This article explores the implications for BD teams, investors, and analysts.
Liminatus Acquires InnocsAI: A $320M CAR-T Bet
Liminatus has acquired CAR-T biotech InnocsAI for $320 million in stock, raising questions about its future strategy and market positioning.
FDA in Flux: May 2026 Drug Approvals Update
This newsletter covers the recent FDA drug approvals and their potential impact on the pharmaceutical landscape. Stay informed on the latest regulatory changes.
Best Cancer Stocks for 2026: Investment Insights
This article explores the top cancer stocks for 2026, providing insights for investors and business development teams in the oncology sector.
FDA Fast Track Designation for Oncology Drugs: April 2026 Insights
In April 2026, the FDA granted Fast Track Designation to several oncology drugs, signaling significant advancements in cancer treatment. This article explores the implications for pharmaceutical teams and investors.
BioMarin's SWOT Analysis: Competitive Headwinds in Rare Disease Biotech
This article provides a comprehensive SWOT analysis of BioMarin Pharmaceutical, focusing on its position in the rare disease biotech sector and the competitive landscape it faces.
New FDA Guidance on ENDS and Nicotine Pouch Products
The FDA has issued new guidance regarding enforcement discretion for certain ENDS and nicotine pouch products, signaling significant regulatory updates.
Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights
Regeneron Pharma stock is in the spotlight following significant institutional buying. This article explores the implications for investors and pharma teams.
FDA Alert: Key Updates on Pulmonology Drug Approvals
This article covers recent FDA alerts on pulmonology drug approvals, recalls, and device updates, highlighting their impact on the pharmaceutical landscape.
FDA to Consider Lifting Restrictions on Compounded Peptides
The FDA is evaluating the potential lifting of restrictions on compounded peptides, which could significantly influence drug approvals and market dynamics. This decision may open new avenues for investment and development in the pharmaceutical sector.
FDA Expands Market Access for ENDS Products: What You Need to Know
The FDA has authorized new ENDS products, expanding market access. This article explores the implications for pharmaceutical teams and investors.
Migraine Drugmaker's Reverse Merger: Market Insights
A migraine drugmaker is set to enter public markets through a reverse merger. This article analyzes the market implications for investors and pharma teams.
Will 2026 Be Pharma’s M&A Breakout Year? Market Analysis
As the pharmaceutical industry anticipates 2026, we analyze potential M&A trends and their implications for business development teams and investors.
Takeda and Novartis Layoffs: Implications for Pharma Industry
Takeda announces a reduction of 4,500 jobs while Novartis lays off biomedical research staff. This article explores the implications for the pharma sector.
OCT East Coast 2026: Key Insights and Highlights
The OCT East Coast 2026 event brought together industry leaders to discuss pivotal developments in the pharma landscape. Here are the key takeaways and insights from the event.
THMA CPE Circle 2026: Key Insights and Highlights
The THMA CPE Circle 2026 brought together industry leaders to discuss pivotal developments in pharma. Key insights and takeaways are outlined for B2B readers.
Fierce Biotech Week 2026: Key Insights and Highlights
Fierce Biotech Week 2026 brought together industry leaders to discuss pivotal developments in biotech. Here are the key insights and highlights from the event.
SELLAS Nears Key AML Data: Insights for Investors and BD Teams
SELLAS Life Sciences is on the verge of releasing critical data from its dual trials for acute myeloid leukemia, presenting significant investment opportunities.
FDA's Bayesian Methodology: A Game Changer for Drug Development
The FDA's recent adoption of Bayesian methodology is set to transform clinical trial justification, impacting biosimilars and broader drug development strategies.